期刊
FUTURE MICROBIOLOGY
卷 17, 期 1, 页码 41-57出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fmb-2021-0094
关键词
antileishmanials; drug discovery; leishmaniasis; molecular pathways
类别
资金
- Jawaharlal Nehru University
Leishmaniasis, the second-largest parasitic disease, lacks a licensed vaccine and treatment mainly relies on chemotherapy, facing issues such as inefficiency and drug resistance. Identifying novel molecular drug candidates is crucial in developing robust antileishmanials, with structure-based drugs targeting Leishmania enzymes/molecules offering a potential solution and insight into Leishmania biology.
The illness known as leishmaniasis has not become a household name like malaria, although it stands as the second-largest parasitic disease, surpassed only by malaria. As no licensed vaccine is available, treatment for leishmaniasis mostly relies on chemotherapy. Inefficiency and drug resistance are the major impediments in current therapeutics. In this scenario, identification of novel molecular drug candidates is indispensable to develop robust antileishmanials. The exploration of structure-based drugs to target enzymes/molecules of Leishmania which differ structurally/functionally from their equivalents in mammalian hosts not only helps in developing a new class of antileishmanials, but also paves the way to understand Leishmania biology. This review provides a comprehensive overview on possible drug candidates relating to various Leishmania molecular pathways.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据